Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 2
2017 2
2018 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG; BMT CTN 1703 Investigators. Bolaños-Meade J, et al. N Engl J Med. 2023 Jun 22;388(25):2338-2348. doi: 10.1056/NEJMoa2215943. N Engl J Med. 2023. PMID: 37342922 Free PMC article. Clinical Trial.
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. J Clin Oncol. 2024 Mar 12:JCO2302474. doi: 10.1200/JCO.23.02474. Online ahead of print. J Clin Oncol. 2024. PMID: 38471061
Reply: To PMID 24395623.
Martinez M, Tandra A, Vuppalanchi R. Martinez M, et al. Among authors: tandra a. Hepatology. 2015 Apr;61(4):1436-7. doi: 10.1002/hep.27351. Epub 2015 Mar 9. Hepatology. 2015. PMID: 25088938 No abstract available.
Reply: To PMID 24395623.
Martinez M, Tandra A, Vuppalanchi R. Martinez M, et al. Among authors: tandra a. Hepatology. 2015 Jun;61(6):2119-20. doi: 10.1002/hep.27542. Epub 2015 Apr 18. Hepatology. 2015. PMID: 25266638 No abstract available.
Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.
Caldemeyer LE, Akard LP, Edwards JR, Tandra A, Wagenknecht DR, Dugan MJ. Caldemeyer LE, et al. Among authors: tandra a. Biol Blood Marrow Transplant. 2017 Nov;23(11):1989-1997. doi: 10.1016/j.bbmt.2017.07.007. Epub 2017 Jul 13. Biol Blood Marrow Transplant. 2017. PMID: 28712934 Free article.